Federal Register Notice
UnitedHealth Group and DaVita; Analysis of Agreement Containing Consent Orders To Aid Public Comment
Date
Displaying 361 - 380 of 1515
Joint Statement of Commissioners Phillips and Wilson Concerning UnitedHealth Group and DaVita
Date
By
Noah Joshua Phillips, Former Commissioner;
Christine S. Wilson, Former Commissioner
Matter Number
181 0057
File
Joint Statement of Commissioners Rohit Chopra and Rebecca Kelly Slaughter Concerning UnitedHealth Group and DaVita
Date
By
Rohit Chopra, Former Commissioner;
Rebecca Kelly Slaughter, Commissioner
Matter Number
181 0057
File
FTC Imposes Conditions on UnitedHealth Group’s Proposed Acquisition of DaVita Medical Group
Date
Healthcare provider and insurer UnitedHealth Group Incorporated and healthcare provider DaVita, Inc. have agreed to a settlement to resolve Federal Trade Commission allegations that UnitedHealth Group...
FTC to Hold Workshop Tomorrow Regarding the Impact of Certificates of Public Advantage
Date
WHAT: The Federal Trade Commission will host a workshop titled A Health Check on COPAs . FTC Chairman Joseph J. Simons will give the opening address. WHEN: Tuesday June 18, 9 a.m.-5 p.m. EDT WHERE...
FTC Announces Agenda for June 18 Workshop, A Health Check on COPAs
Date
The Federal Trade Commission has announced an agenda for its upcoming workshop in Washington, DC regarding the impact of certificates of public advantage, also known as COPAs, on prices, quality...
FTC Submits Comment on Proposed Information Blocking Rule to the Department of Health & Human Services Office of the National Coordinator for Health Information Technology (ONC)
Date
The Federal Trade Commission staff has submitted a comment to the Department of Health & Human Services’ Office of the National Coordinator for Health Information Technology , or ONC, regarding ONC’s...
FTC Staff Comment Before the Department of Health and Human Services Regarding the 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program
Date
Matter Number
V190002
Docket Number
RIN 0955-AA01
FTC Staff Comment to the FDA Department of Health and Human Services on Its Updated Guidance for Industry on the “Nonproprietary Naming of Biological Products”
Date
Matter Number
V190001
Docket Number
FDA-2013-D-1543
File
Text of the FTC Staff Comment
(52.95 KB)
FTC Submits Comment on FDA Guidance Regarding Nonproprietary Naming of Biological Products
Date
The Federal Trade Commission staff has responded to the Food and Drug Administration’s request for comment on its updated industry guidance regarding nonproprietary naming of biological products. The...
Administrative Law Judge Upholds FTC’s Complaint Challenging Consummated Merger of Companies that Make Microprocessor Prosthetic Knees
Date
In an Initial Decision announced today, Chief Administrative Law Judge D. Michael Chappell upheld a Federal Trade Commission complaint challenging the consummated merger of two prosthetics...
FTC Charges Surescripts with Illegal Monopolization of E-Prescription Markets
Date
The Federal Trade Commission sued the health information company Surescripts, alleging that the company employed illegal vertical and horizontal restraints in order to maintain its monopolies over two...
FTC to Hold Workshop on Certificates of Public Advantage in Healthcare Markets
Date
On June 18, 2019, the Federal Trade Commission will hold a public workshop in Washington, DC to assess the impact of certificates of public advantage (“COPAs”) on prices, quality, access, and...
FTC Approves Final Order Imposing Conditions on Merger of Fresenius Medical Care AG & KGaA and NxStage Medical, Inc.
Date
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Fresenius Medical Care AG’s proposed $2 billion acquisition of NxStage Medical, Inc...
Fresenius Medical Care and NxStage Medical, In the Matter of
The FTC required healthcare companies Fresenius Medical Care AG & KGaA and NxStage Medical, Inc. to divest all rights and assets related to NxStage’s bloodline tubing set business to B. Braun Medical, Inc. as part of a settlement resolving charges that Fresenius’s proposed $2 billion acquisition of NxStage likely would be anticompetitive. The FTC’s complaint alleges that the proposed merger would harm competition in the U.S. market for bloodline tubing sets that are compatible with hemodialysis machines used in clinics that treat chronic renal failure. Bloodline tubing sets are single-use plastic tube sets used during hemodialysis treatments. Fresenius and NxStage are two of only three significant suppliers of bloodline tubing sets used in open architecture hemodialysis machines in the United States. Fresenius and NxStage together control 82 percent of the market for bloodlines.The settlement requires Fresenius and NxStage to divest to B. Braun all assets and rights to research, develop, manufacture, market, and sell NxStage’s bloodline tubing sets.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
171 0227
C-4671
FTC Concludes that Impax Entered into Illegal Pay-for-Delay Agreement
Date
The Federal Trade Commission announced its Opinion and Final Order against generic pharmaceutical company Impax Laboratories LLC . The Commission ruled that Impax engaged in an illegal pay-for-delay...
FTC Staff Testifies in Favor of Repealing Alaska Laws that Limit Competition in the Health Care Sector
Date
Federal Trade Commission staff has recommended that Alaska pass Senate Bill 1, which would repeal its certificate-of-need (CON) law. Alaska’s CON law requires healthcare providers to obtain state...
Displaying 361 - 380 of 1515